{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"12"}]}],"title":"Responder"},{"categories":[{"measurements":[{"groupId":"OG000","value":"8"}]}],"title":"Non-Responder"}],"denoms":[{"counts":[{"groupId":"OG000","value":"20"}],"units":"Participants"}],"description":"Patients who demonstrate a PR or CR, as defined below, will be considered as responders. RECIST criteria: CR (complete response) = disappearance of all target lesions, PR (partial response) = 30% decrease in the sum of the longest diameter of target lesions, PD (progressive disease) = 20% increase in the sum of the longest diameter of target lesions and SD (stable disease) = small changes that do not meet above criteria.","groups":[{"description":"Patients receive paclitaxel IV over 3 hours and carboplatin IV over 1 hour on day 1 and ifosfamide IV over 1 hour on days 1-5. Beginning on day 6, patients receive filgrastim (G-CSF) subcutaneously or IV once daily until blood count returns to normal. Treatment repeats every 21 days for 2 courses in the absence of disease progression or unacceptable toxicity.\n\npaclitaxel: Given IV dosage 135 mg/m2/dose\n\ncarboplatin: Given IV dosage in mg/m2 = Target AUC (mg•min/mL) x \\[(0.93 x GFR mL/min/m2) + 15\\]= 6.5 x \\[(0.93 x GFR mL/min/m2) + 15\\]. (BSA = body surface area in square meters). GFR is reported in institutions as \"uncorrected\" or \"raw\" (not normalized to BSA) or \"corrected.\" This number needs to be converted to GFR in mL/min/m2.\n\nifosfamide: Given IV dosage 1800 mg/m2/dose\n\nfilgrastim: Given IV or subcutaneously dosage 1,080mg/m2/day divided to three equal doses of 360mg/m2\n\nlaboratory biomarker analysis: Optional correlative studies","id":"OG000","title":"Treatment (Chemotherapy, Biological Therapy)"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"At baseline (day 1) and after completion of protocol therapy (2 cycles or 42 days)","title":"Response Rate as Measured by Response Evaluation Criteria in Solid Tumors (RECIST) Criteria","type":"PRIMARY","unitOfMeasure":"participants"}